期刊文献+

磷酸二酯酶-4抑制剂阿普司特 被引量:12

A phosphodiesterase-4 inhibitor apremilast
原文传递
导出
摘要 银屑病是一种常见的皮肤疾病,其特征是慢性炎症性病变,长期困扰患者且不易为医生治疗。虽然有多种治疗方案可供选择,但都有其局限性,因此急需一种有效、安全的口服治疗银屑病的药物。阿普司特作为磷酸二酯酶-4(PDE-4)抑制剂,是一种口服药物,抑制参与银屑病发病机制中的多个炎症标志物的活性,可有效治疗银屑病。阿普司特在一系列临床研究中显示出良好的治疗前景,且安全性及耐受性均较好。 Psoriasis is a common skin disorder characterized by chronic inflammatory lesions. Patients are frequently troubled by it and it is difficult for doctor to cure. Although multiple therapeutic options are available, they all have limitations. There is an urgent need for an effective, safe, and oral drug used in clinic for the treatment of psoriasis. Apremilast, as an inhibitor of phosphodiesterase-4 (PDE-4), is an oral medication that inhibits the activity of multiple inflammatory markers involved in the pathogenesis of psoriasis. It can be used to treat psoriasis effectively, which shows a good prospect in a series of clinical studies with good safety and tolerability.
出处 《现代药物与临床》 CAS 2014年第4期428-433,共6页 Drugs & Clinic
基金 天津市科技计划项目(13ZCZDSY00100)
关键词 阿普斯特 磷酸二酯酶-4抑制剂 银屑病 口服靶向药物 : apremilast phosphodiesterase-4 inhibitor psoriasis oral target drugs
  • 相关文献

参考文献22

  • 1Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis [J]. Biochem Pharmacol, 2012, 83: 1583-1590.
  • 2Papp K, Cather J C, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial [J]. Lancet, 2012, 380(9843): 738-746.
  • 3Schafer P H, Parton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase4 inhibitor, demonstrates anti- inflammatory activity in vitro and in a model of psoriasis [J]. BrJPharmacol, 2010, 159: 842-855.
  • 4McCann F E, Palfreeman A C, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis [J]. Arthritis Res Ther, 2010, 12(3): R107.
  • 5Gottlieb A B, Strober B, Krueger J G, et al. An open-label, single-arm pilot study in patients withsevere plaque-type psoriasis treated with an oral antiinflammatory agent, apremilast [J]. Curr Med Res Opin, 2008, 24(5): ! 529-1538.
  • 6Capone L, Rogovitz A, Gandhi A K, et al. Antiinflammatory activity of apremilast against T cells, chondrocytes, andrheumatoid arthritis synovial fibroblasts in vitro [R]. Chicago: annual scientific meeting of the American College of Rheumatology, 2011.
  • 7Serezani C H, Ballinger M N, Aronoff D M, et al. Cyclic AMP: master regulator of innate immune cell function [J]. Am J Respir Cell Mol Biol, 2008, 39(2): 127-132.
  • 8Schett G, Sloan V S, Stevens R M, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases [J]. Ther Adv Musculoskelet Dis, 2010, 2(5): 271-278.
  • 9Man H W, Schafer P, Wong L M, et al. Discovery of (S)-N- [2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]- 1,3-dioxo-2,3-dihydro-lH-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis fhctor-ct inhibitor [J]. J Med Chem, 2009, 52(6): 1522-1524.
  • 10Schafer P H, Patton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti- inflammatory activity in vitro and in a model of psoriasis [J]. BrJPharmacol, 2010, 159(4): 842-855.

同被引文献122

  • 1康景华,李正翔,刘宏祥.凉血化斑颗粒治疗常见皮肤病500例临床观察[J].中草药,2007,38(4):586-587. 被引量:4
  • 2Colsman A, Carrascosa J M, Ferrandiz C, et al. Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab [J]. J Eur Acad Dermatol Venereol, 2008, 22(9): 1131-1134.
  • 3Kagami S, Rizzo H L, Lee J J, et al. Circulating Thl7, Th22 and Thl cells are increased in psoriasis [J]. Jlnvest Dermatol, 2010, 130(5): 1373-1383.
  • 4Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randornizedcontrolled trial [J]. J Clin Immunol, 2009, 29(2): 210-214.
  • 5Antiga E, Volpi W, Chiarini C, et al. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris [J]. lnt J lmmunopathol Pharmacol, 2010, 23(3): 767-774.
  • 6Zaba L C, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Thl7 responses [J]. J Exp Med, 2007, 204(13): 3183-3194.
  • 7Brown S L, Greene M H, Gershon S K, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration [J]. Arthritis Rheum, 2002, 46(12): 3151-3158.
  • 8Antoni C, Krueger G C, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J]. Ann Rheum Dis, 2005, 64(8): 1150-1157.
  • 9Menter A, Feldman S R, Weinstein G D, et al. A randomized comparisonof continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis [J]. J Am AcadDermatol, 2007, 56(1): 31.
  • 10Antoniou C, Stefanaki I, Stratigos A, et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre [J]. Br J Dermatol, 2010, 162(5): 1117-1123.

引证文献12

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部